Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases
To see Spark’s full report on ZURA stock, click here.
Model output · Signal date 2026-10-20
Zura Bio Ltd (ZURA) Stock Forecast Oct. 20, 2026
Analysis updated on Oct. 20, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 4016 stocks scored
Rank correlation · 90D
15.0%
Spearman, 317 dates
Market Cap
$365M
small-cap · #60 of 60 peers
Summary
Zura Bio Ltd (ZURA) stock forecast summary
Our AI ranks Zura Bio Ltd outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Zura Bio Ltd is a small-cap company with a market capitalization of $365M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For ZURA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 317 forecast dates between 2023-05-16 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 359 forecast dates between 2023-05-16 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-20 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ZURA included.
Follow ZURA freePrice
ZURA price chart and AI forecast
Cross-section · 2026-10-20
How ZURA ranks among 4016 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Zura Bio Ltd (ZURA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | ZURA | Rank |
|---|---|---|
| Market Cap | $365M | 60/60 |
| P/B Ratio | 1.85x | 45/50 |
| EPS | $-1.10 | – |
| Book Value/Share | $2.06 | – |
| FCF/Share | $-0.39 | – |
Profitability & Margins
| Metric | ZURA | Rank |
|---|---|---|
| ROE | -43.5% | 30/48 |
| ROA | -40.2% | 36/51 |
| ROIC | -47.1% | 40/53 |
| Tax Rate | 9.1% | – |
Financial Health
| Metric | ZURA | Rank |
|---|---|---|
| Current Ratio | 12.90x | 12/59 |
| D/E Ratio | 0.08x | 50/53 |
| Financial Leverage | 1.08x | 49/52 |
| Working Capital | $194M | 49/59 |
Cash Flow
| Metric | ZURA | Rank |
|---|---|---|
| Operating Cash Flow | -$38M | 22/57 |
| Free Cash Flow | -$38M | 19/50 |
| Capital Spending | -$50K | 1/50 |
Income Statement
| Metric | ZURA | Rank |
|---|---|---|
| Operating Income | -$93M | 21/54 |
| Net Income | -$86M | 20/51 |
| R&D Expense | $58M | 50/56 |
Dividend & Shareholder Information
| Metric | ZURA | Rank |
|---|---|---|
| Shares Outstanding | 96M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $210M | 98.5% of assets |
| Cash & Short-term Investments | $205M | 96.0% of assets |
| Total Liabilities | $16M | 7.6% of assets |
| Short-term Debt | $13M | 6.1% of assets |
Quarterly Financial Reports
ZURA quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd (ZURA) industry peers
Companies classified under the same SEC industry code as Zura Bio Ltd (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ZURA Zura Bio Ltd | ▲ | $365M |
| AMGN Amgen Inc | ▼ | $229.74B |
| GILD Gilead Sciences, Inc. | ▲ | $189.80B |
| MRNA Moderna, Inc. | ▲ | $90.58B |
| ARGX Argenx Se | ▼ | $51.09B |
| RVMD Revolution Medicines, Inc. | ▲ | $39.04B |
| BIIB Biogen Inc. | ▼ | $34.25B |
| BNTX Biontech Se | ▲ | $22.56B |
| EXEL Exelixis, Inc. | ▶ | $15.53B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.90B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| QGEN Qiagen N.V. | ▶ | $10.10B |
| RGEN Repligen Corp | ▲ | $9.96B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.48B |
| PCVX Vaxcyte, Inc. | ▲ | $9.48B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B |
| IBRX Immunitybio, Inc. | ▲ | $8.92B |
| TWST Twist Bioscience Corp | ▲ | $8.76B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B |
| KOD Kodiak Sciences Inc. | ▲ | $5.74B |
| IMVT Immunovant, Inc. | ▲ | $5.70B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.90B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.82B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.75B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.05B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.88B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.50B |
| ADMA Adma Biologics, Inc. | ▼ | $2.48B |
| LIFE Atyr Pharma Inc | ▲ | $2.48B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.16B |
| VCEL Vericel Corp | ▶ | $2.07B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| ALVO Alvotech | ▲ | $1.80B |
| NVAX Novavax Inc | ▲ | $1.78B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.73B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.65B |
| MESO Mesoblast Ltd | ▶ | $1.55B |
| IMCR Immunocore Holdings Plc | ▶ | $1.54B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.50B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.28B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.04B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $945M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $909M |
| MGTX Meiragtx Holdings Plc | ▶ | $908M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $900M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $870M |
| PRME Prime Medicine, Inc. | ▲ | $695M |
| SANA Sana Biotechnology, Inc. | ▲ | $689M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $679M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $678M |
| AURA Aura Biosciences, Inc. | ▲ | $652M |
| SLDB Solid Biosciences Inc. | ▲ | $635M |
| CADL Candel Therapeutics, Inc. | ▲ | $628M |
| DBVT Dbv Technologies S.A. | ▶ | $531M |
Where ZURA sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Zura Bio Ltd (ZURA) stock news
Athanor Capital, LP Adjusts Stake in Zura Bio Ltd
Zura Bio Ltd, which went public on March 21, 2023, is a clinical-stage biotechnology company dedicated to developing treatments for immune and inflammatory disorders. With a market capitalization of ...
Zura Bio Ltd stock (KYG989201089): Is its immunology pipeline strong enough to unlock biotech upside?
Zura Bio's focus on autoimmune diseases positions it in a high-growth biotech niche, but execution risks remain key for investors. Here's why U.S. and global readers should watch its clinical progress ...
FAQ
Zura Bio Ltd (ZURA) stock forecast FAQ
What is the Zura Bio Ltd (ZURA) stock forecast?
Our AI ranks Zura Bio Ltd outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Zura Bio Ltd stock predictions?
For ZURA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 317 forecast dates between 2023-05-16 and 2026-07-22 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 359 forecast dates between 2023-05-16 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Zura Bio Ltd forecasts updated?
Zura Bio Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 20, 2026.
Which companies are Zura Bio Ltd's industry peers?
60 issuers in our coverage, ZURA included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.